Differential Diagnoses for Hematuria in Male Patients
In male patients with hematuria, the differential diagnosis must be systematically categorized into malignant and benign causes, with malignancy being the primary concern that must be excluded—particularly bladder cancer, which accounts for most cancers diagnosed in patients with hematuria. 1
Malignant Causes (Primary Concern)
Urothelial carcinoma (bladder cancer, upper tract urothelial carcinoma) represents the most critical diagnosis to exclude, as:
- Gross hematuria carries a 30-40% malignancy risk 1
- Microhematuria carries a 2.6-4% malignancy risk 1
- Delays in bladder cancer diagnosis increase cancer-specific mortality by 34% and all-cause mortality by 15% 2
Renal cell carcinoma and other urinary tract malignancies can occur anywhere along the urinary tract 1
Risk Factors That Increase Malignancy Probability:
- Male gender (inherent risk factor) 1
- Age >35 years 1
- Smoking history (causal association with bladder and kidney cancer) 2, 1
- Occupational chemical exposures 1
- History of pelvic irradiation 1
- Chronic urinary tract infections 1
- Exposure to chemotherapy (cyclophosphamide) or carcinogenic agents 1
- Chronic indwelling foreign body 1
- Analgesic abuse 1
- Irritative voiding symptoms 1
Benign Urogenic (Non-Glomerular) Causes
Most Common in Males:
Benign prostatic hyperplasia (BPH) - extremely common in older males, requires digital rectal examination before imaging 1
Urolithiasis (kidney stones, ureteral stones) - one of the three most common benign causes 1
Urinary tract infection - must be confirmed with urine culture (preferably before antibiotics); hematuria should resolve after appropriate treatment, and persistence warrants full workup 1
Urethral stricture disease - evaluated with cystoscopy 3
Trauma (including iatrogenic from recent urologic procedures, catheterization, or device migration) 1, 4
Vigorous exercise - transient cause in low-risk patients 1
Nephrogenic (Glomerular/Renal Parenchymal) Causes
Renal parenchymal disease is the most common benign nephrogenic cause 1:
- Glomerulonephritis
- Glomerulonephropathy
- Acute tubular necrosis
- Acute kidney injury
Key Indicators of Glomerular Disease:
- Dysmorphic red blood cells
- Cellular casts
- Proteinuria
- Elevated serum creatinine
- Hypertension
These findings mandate concurrent nephrology referral while not precluding urologic evaluation 1, 3
Risk Stratification Approach (2025 AUA/SUFU Update)
The 2025 guideline introduces a revised risk stratification system with three categories 2:
- Low/negligible risk: 0-0.4% malignancy rate
- Intermediate risk: 0.2-3.1% malignancy rate
- High risk: 1.3-6.3% malignancy rate
This stratification should guide the intensity of evaluation, with higher-risk patients requiring comprehensive workup including cystoscopy and upper tract imaging.
Critical Clinical Pitfalls
Do not attribute hematuria solely to anticoagulation - anticoagulant therapy does not alter the need for urologic evaluation 1
Do not skip evaluation in patients with identified benign causes - unless the patient is low-risk without malignancy risk factors, a benign cause does not exclude concurrent malignancy 1
Persistent hematuria after UTI treatment requires full diagnostic workup 1, 3
Gross hematuria always requires full urologic workup regardless of other findings, given the 30-40% malignancy association 1